Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention
Open Access
- 5 August 2011
- journal article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 43 (7) , 531-544
Abstract
Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis-à-vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.Keywords
This publication has 92 references indexed in Scilit:
- Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery diseaseEuropean Heart Journal, 2010
- Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic DiseaseClinical and Applied Thrombosis/Hemostasis, 2010
- Platelet thrombin receptor antagonism and atherothrombosisEuropean Heart Journal, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Pharmacology of emerging novel platelet inhibitorsAmerican Heart Journal, 2008
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trialAmerican Heart Journal, 2007
- Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES RegistryHeart, 2006
- A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk PatientsNew England Journal of Medicine, 1989